Servier said its experimental muscular dystrophy drug sevasemten failed a pivotal trial, marking a significant reversal for a program acquired for $1.55 billion plus potential milestones from Edgewise Therapeutics. In the long placebo-controlled GRAND CANYON study in Becker muscular dystrophy, results did not show statistically significant benefit in the pivotal cohort. Servier acknowledged the discrepancy with earlier findings from prior studies and said it is conducting a comprehensive analysis of the dataset alongside relevant clinical history to better characterize the findings. The failure resets expectations for a patient population with no approved treatments, while also reopening questions about trial design and effect size assumptions for dystrophy endpoints. It further increases pressure on sponsors to ensure early-stage signals translate into late-stage efficacy. The setback also matters for the broader industry because it reinforces how high-cost late-stage investments remain vulnerable even when smaller randomized studies show promise.